CDC Website CDC Website

To Join the NPIN community or

You are here

Colleges/Universities

COVID-19: General Information | Testing | Vaccines |

Contact Organizations directly about changes to services or hours

The role of Epstein Barr virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection (U01 Clinical Trial Optional)

The role of EBV infection on Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection and AIDS will increase our understanding through mechanistic, epidemiological, or translational studies that examine how EBV promotes NHL or HD initiation, progression and the resulting disease sequelae. In addition, insights into mechanistic differences of EBV infection and lymphomagenesis between HIV positive and HIV negative persons will be gained.

AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)

This funding opportunity announcement (FOA) seeks to facilitate the entry of both newly independent and early career investigators to the area of drug use and use disorder research and HIV/AIDS. This FOA, the AIDS-Science Track Award for Research Transition (A-START), encourages Small Research Grant (R03) applications to support research projects on drug use and/or use disorder and HIV/AIDS that can be carried out in a short period of time with limited resources.

High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use.

Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R43/R44 Clinical Trial Not Allowed)

The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative long-acting systemic and non-systemic multipurpose prevention technologies (MPT). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods) in adolescent and young women. Applications for MPT development may involve pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies.

HIV Prevention and Alcohol (R01 Clinical Trials Optional)

The FOA seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research.

HIV Prevention and Alcohol (R34 Clinical Trials Optional)

The FOA seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research.

Emerging Infections Sentinel Networks (EISN) Research

The purpose of this Notice of Funding Opportunity (NOFO) is to provide a funding mechanism for Emerging Infections Sentinel Networks (EISN) research activities, specifically within a network of emergency departments (EDs). The EISN program will assist in operating emergency department provider-based sentinel networks.

Pages

Subscribe to RSS - Colleges/Universities